Turn Therapeutics Inc. (TTRX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-98.2%

$0.18

vs $9.65 price

Levered DCF

$0.36

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

7.69

Safe zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022
P/E	-17.13×	-53.85×	-41.18×	-21.21×
P/B	11.55×	-529.55×	1,081.18×	79.84×
P/S	0×	0×	0×	0×
EV / EBITDA	-15.65×	-54.16×	-40.73×	-21.7×
Gross margin	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%
Current ratio	0.87×	1.55×	2.45×	1.23×
Debt / equity	0.02×	-0.68×	0.29×	0.07×
Interest coverage	0×	0×	0×	-49.3×
Dividend yield	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022
Return on equity	-68.2%	996.7%	-2672.6%	-371.1%
Return on invested capital	-94.4%	-130.1%	-149.0%	-339.8%
Return on assets	-26.3%	-86.3%	-113.8%	-147.1%
Free cash flow yield	-5.0%	-1.6%	-1.5%	-1.3%
Earnings yield	-5.9%	-1.9%	-2.5%	-4.6%
Enterprise value	$49.2M	$93.2M	$91.6M	$90.2M
Net debt / EBITDA	1.59×	0.44×	0.51×	0.49×
Cash conversion cycle (days)	0	0	0	-1,771